Yongfeng Yang, Tingting Song, Sha Liu, Zhiqiang Liu, Xuehui Wang, Yi Li, Dan Liu
{"title":"Circle-map profiling of extrachromosomal circular DNA as diagnostic biomarkers for lung cancer","authors":"Yongfeng Yang, Tingting Song, Sha Liu, Zhiqiang Liu, Xuehui Wang, Yi Li, Dan Liu","doi":"10.1093/pcmedi/pbae006","DOIUrl":"https://doi.org/10.1093/pcmedi/pbae006","url":null,"abstract":"","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140211852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jiahui Li, Simiao Zeng, Zhihuan Li, Jie Xu, Zhuo Sun, Jing Zhao, Meiyan Li, Zixing Zou, Taihua Guan, Jin Zeng, Zhuang Liu, Wenchao Xiao, Ran Wei, Hanpei Miao, Ian Ziyar, Junxiong Huang, Yuanxu Gao, Yangfa Zeng, Xing-Tao Zhou, Kang Zhang
Myopia is a leading cause of visual impairment in Asia and worldwide. However, accurately predicting the progression of myopia and the high risk of myopia remains a challenge. This study aims to develop a predictive model for the development of myopia. We first retrospectively gathered 612 530 medical records from five independent cohorts, encompassing 227 543 patients ranging from infants to young adults. Subsequently, we developed a multivariate linear regression algorithm model to predict the progression of myopia and the risk of high myopia. The model to predict the progression of myopia achieved an R-squared (R2) value of 0.964 vs a mean absolute error (MAE) of 0.119D (95% CI: 0.119, 1.146) in the internal validation set. It demonstrated strong generalizability, maintaining consistent performance across external validation sets: R2 of 0.950 vs MAE of 0.119D (95% CI: 0.119, 1.136) in validation Study 1, R2 of 0.950 vs MAE of 0.121D (95% CI: 0.121, 1.144) in validation Study 2, and R2 of 0.806 vs MAE of −0.066D (95% CI: −0.066, 0.569) in Shanghai Children Myopia Study. Beijing Children Eye Study, the model sustained R2 of 0.749 vs MAE of 0.178D (95% CI: 0.178, 1.557). The model to predict the risk of high myopia achieved and an area under the curve (AUC) of 0.99 in the internal validation set and consistently high AUC values of 0.99, 0.99,0.96 and 0.99 in the respective external validation sets. Our study demonstrates accurate prediction of myopia progression and risk of high myopia providing valuable insights for tailoring strategies to personalize and optimize the clinical management of myopia in children.
近视是亚洲乃至全球视力受损的主要原因。然而，准确预测近视的发展和近视的高风险仍然是一项挑战。本研究旨在建立近视发展的预测模型。 我们首先回顾性地收集了来自五个独立队列的 612 530 份病历，其中包括 227 543 名从婴儿到青年的患者。随后，我们建立了一个多变量线性回归算法模型来预测近视的发展和高度近视的风险。 在内部验证集中，预测近视发展的模型的 R 平方 (R2) 值为 0.964，而平均绝对误差 (MAE) 为 0.119D (95% CI: 0.119, 1.146)。它具有很强的普适性，在外部验证集上保持了一致的性能：在验证研究 1 中，R2 为 0.950 vs MAE 为 0.119D (95% CI: 0.119, 1.136)；在验证研究 2 中，R2 为 0.950 vs MAE 为 0.121D (95% CI: 0.121, 1.144)；在上海儿童近视研究中，R2 为 0.806 vs MAE 为 -0.066D (95% CI: -0.066, 0.569)。在北京儿童眼科研究中，该模型的 R2 为 0.749，而 MAE 为 0.178D (95% CI: 0.178, 1.557)。预测高度近视风险的模型在内部验证集中的曲线下面积（AUC）达到了 0.99，在外部验证集中的曲线下面积（AUC）也分别达到了 0.99、0.99、0.96 和 0.99。 我们的研究证明了对近视发展和高度近视风险的准确预测，为定制个性化和优化儿童近视临床管理的策略提供了宝贵的见解。
{"title":"Accurate prediction of myopic progression and high myopia by machine learning","authors":"Jiahui Li, Simiao Zeng, Zhihuan Li, Jie Xu, Zhuo Sun, Jing Zhao, Meiyan Li, Zixing Zou, Taihua Guan, Jin Zeng, Zhuang Liu, Wenchao Xiao, Ran Wei, Hanpei Miao, Ian Ziyar, Junxiong Huang, Yuanxu Gao, Yangfa Zeng, Xing-Tao Zhou, Kang Zhang","doi":"10.1093/pcmedi/pbae005","DOIUrl":"https://doi.org/10.1093/pcmedi/pbae005","url":null,"abstract":"\u0000 \u0000 \u0000 Myopia is a leading cause of visual impairment in Asia and worldwide. However, accurately predicting the progression of myopia and the high risk of myopia remains a challenge. This study aims to develop a predictive model for the development of myopia.\u0000 \u0000 \u0000 \u0000 We first retrospectively gathered 612 530 medical records from five independent cohorts, encompassing 227 543 patients ranging from infants to young adults. Subsequently, we developed a multivariate linear regression algorithm model to predict the progression of myopia and the risk of high myopia.\u0000 \u0000 \u0000 \u0000 The model to predict the progression of myopia achieved an R-squared (R2) value of 0.964 vs a mean absolute error (MAE) of 0.119D (95% CI: 0.119, 1.146) in the internal validation set. It demonstrated strong generalizability, maintaining consistent performance across external validation sets: R2 of 0.950 vs MAE of 0.119D (95% CI: 0.119, 1.136) in validation Study 1, R2 of 0.950 vs MAE of 0.121D (95% CI: 0.121, 1.144) in validation Study 2, and R2 of 0.806 vs MAE of −0.066D (95% CI: −0.066, 0.569) in Shanghai Children Myopia Study. Beijing Children Eye Study, the model sustained R2 of 0.749 vs MAE of 0.178D (95% CI: 0.178, 1.557). The model to predict the risk of high myopia achieved and an area under the curve (AUC) of 0.99 in the internal validation set and consistently high AUC values of 0.99, 0.99,0.96 and 0.99 in the respective external validation sets.\u0000 \u0000 \u0000 \u0000 Our study demonstrates accurate prediction of myopia progression and risk of high myopia providing valuable insights for tailoring strategies to personalize and optimize the clinical management of myopia in children.\u0000","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140080308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Owing to its constant exposure to the external environment and various stimuli, skin ranks among the organs most vulnerable to manifestations of aging. Preventing and delaying skin aging has become one of the prominent research subjects in recent years. Mesenchymal stem cells (MSCs) are multipotent stem cells derived from mesoderm with high self-renewal ability and multilineage differentiation potential. MSC-derived extracellular vesicles (MSC-EVs) are nanoscale biological vesicles that facilitate intercellular communication and regulate biological behavior. Recent studies have shown that MSC-EVs have potential applications in anti-aging therapy due to their anti-inflammatory, anti-oxidative stress, and wound healing promoting abilities. This review presents the latest progress of MSC-EVs in delaying skin aging. It mainly includes the MSC-EVs promoting the proliferation and migration of keratinocytes and fibroblasts, reducing the expression of matrix metalloproteinases, resisting oxidative stress, and regulating inflammation. We then briefly discuss the recently discovered treatment methods of MSC-EVs in the field of skin anti-aging. Moreover, the advantages and limitations of EV-based treatments are also presented.
{"title":"Extracellular vesicles derived from mesenchymal stem cells: the wine in Hebe's hands to treat skin aging.","authors":"Qixiang Gui, Neng Ding, Zuochao Yao, Minjuan Wu, Ruifeng Fu, Yue Wang, Yunpeng Zhao, Lie Zhu","doi":"10.1093/pcmedi/pbae004","DOIUrl":"10.1093/pcmedi/pbae004","url":null,"abstract":"<p><p>Owing to its constant exposure to the external environment and various stimuli, skin ranks among the organs most vulnerable to manifestations of aging. Preventing and delaying skin aging has become one of the prominent research subjects in recent years. Mesenchymal stem cells (MSCs) are multipotent stem cells derived from mesoderm with high self-renewal ability and multilineage differentiation potential. MSC-derived extracellular vesicles (MSC-EVs) are nanoscale biological vesicles that facilitate intercellular communication and regulate biological behavior. Recent studies have shown that MSC-EVs have potential applications in anti-aging therapy due to their anti-inflammatory, anti-oxidative stress, and wound healing promoting abilities. This review presents the latest progress of MSC-EVs in delaying skin aging. It mainly includes the MSC-EVs promoting the proliferation and migration of keratinocytes and fibroblasts, reducing the expression of matrix metalloproteinases, resisting oxidative stress, and regulating inflammation. We then briefly discuss the recently discovered treatment methods of MSC-EVs in the field of skin anti-aging. Moreover, the advantages and limitations of EV-based treatments are also presented.</p>","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10955876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140185854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Meng-ting Shen, Xi Liu, Yue Gao, Rui Shi, Li Jiang, Jin Yao
{"title":"Radiomics-based quantitative contrast-enhanced CT analysis of abdominal lymphadenopathy to differentiate tuberculosis from lymphoma","authors":"Meng-ting Shen, Xi Liu, Yue Gao, Rui Shi, Li Jiang, Jin Yao","doi":"10.1093/pcmedi/pbae002","DOIUrl":"https://doi.org/10.1093/pcmedi/pbae002","url":null,"abstract":"","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139686748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leilei Chen, Yan Wang, Huihui Zhou, Yi Liang, Fengqin Zhu, Guangxi Zhou
Inflammatory bowel diseases, with an increasing incidence, pose a significant health burden. Although there have been significant advances in the treatment of IBD, more progress is still needed. Hyperbaric oxygen therapy (HBOT) has been shown to treat a host of conditions such as carbon monoxide poisoning, decompression sickness, and gas gangrene. In the last few years, there has been an increase in research into the use of HBOT as an adjunct to conventional treatment for IBD. Related researches have shown that HBOT may exert its therapeutic effects by decreasing oxidative stress, inhibiting mucosal inflammation, promoting ulcer healing, influencing gut microbes and reducing the incidence of IBD complications. This paper aims to provide a comprehensive review of experimental and clinical trials exploring hyperbaric oxygen therapy as a supplement to IBD treatment strategies.
{"title":"The new insights of hyperbaric oxygen therapy: focus on inflammatory bowel disease","authors":"Leilei Chen, Yan Wang, Huihui Zhou, Yi Liang, Fengqin Zhu, Guangxi Zhou","doi":"10.1093/pcmedi/pbae001","DOIUrl":"https://doi.org/10.1093/pcmedi/pbae001","url":null,"abstract":"\u0000 Inflammatory bowel diseases, with an increasing incidence, pose a significant health burden. Although there have been significant advances in the treatment of IBD, more progress is still needed. Hyperbaric oxygen therapy (HBOT) has been shown to treat a host of conditions such as carbon monoxide poisoning, decompression sickness, and gas gangrene. In the last few years, there has been an increase in research into the use of HBOT as an adjunct to conventional treatment for IBD. Related researches have shown that HBOT may exert its therapeutic effects by decreasing oxidative stress, inhibiting mucosal inflammation, promoting ulcer healing, influencing gut microbes and reducing the incidence of IBD complications. This paper aims to provide a comprehensive review of experimental and clinical trials exploring hyperbaric oxygen therapy as a supplement to IBD treatment strategies.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139613846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zhen Zeng, Mingshan Jiang, Xi Li, Jing Yuan, Hu Zhang
Inflammatory bowel disease (IBD) is an incurable disease characterized by remission-relapse cycles throughout its course. Both Crohn's disease (CD) and ulcerative colitis (UC), the two main forms of IBD, exhibit tendency to develop complications and substantial heterogeneity in terms of frequency and severity of relapse, thus posing great challenges to the clinical management for IBD. Current treatment strategies are effective in different ways in induction and maintenance therapies for IBD. Recent advances in studies of genetics, pharmacogenetics, proteomics and microbiome provide a strong driving force for identifying molecular markers of prognosis and treatment response, which should help clinicians manage IBD patients more effectively, and then, improve clinical outcomes and reduce treatment costs of patients. In this review, we summarize and discuss precision medicine in IBD, focusing on predictive markers of disease course and treatment response, and monitoring indices during therapeutic drug monitoring.
{"title":"Precision medicine in inflammatory bowel disease","authors":"Zhen Zeng, Mingshan Jiang, Xi Li, Jing Yuan, Hu Zhang","doi":"10.1093/pcmedi/pbad033","DOIUrl":"https://doi.org/10.1093/pcmedi/pbad033","url":null,"abstract":"\u0000 Inflammatory bowel disease (IBD) is an incurable disease characterized by remission-relapse cycles throughout its course. Both Crohn's disease (CD) and ulcerative colitis (UC), the two main forms of IBD, exhibit tendency to develop complications and substantial heterogeneity in terms of frequency and severity of relapse, thus posing great challenges to the clinical management for IBD. Current treatment strategies are effective in different ways in induction and maintenance therapies for IBD. Recent advances in studies of genetics, pharmacogenetics, proteomics and microbiome provide a strong driving force for identifying molecular markers of prognosis and treatment response, which should help clinicians manage IBD patients more effectively, and then, improve clinical outcomes and reduce treatment costs of patients. In this review, we summarize and discuss precision medicine in IBD, focusing on predictive markers of disease course and treatment response, and monitoring indices during therapeutic drug monitoring.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138965021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-11eCollection Date: 2023-12-01DOI: 10.1093/pcmedi/pbad031
Fei Jiang, Min Wu, Rongpeng Li
Inflammatory bowel diseases (IBD) are a group of chronic relapsing gastrointestinal inflammatory diseases with significant global incidence. Although the pathomechanism of IBD has been extensively investigated, several aspects of its pathogenesis remain unclear. Long non-coding RNAs (lncRNAs) are transcripts with more than 200 nucleotides in length that have potential protein-coding functions. LncRNAs play important roles in biological processes such as epigenetic modification, transcriptional regulation and post-transcriptional regulation. In this review, we summarize recent advances in research on IBD-related lncRNAs from the perspective of the overall intestinal microenvironment, as well as their potential roles as immune regulators, diagnostic biomarkers and therapeutic targets or agents for IBD.
{"title":"The significance of long non-coding RNAs in the pathogenesis, diagnosis and treatment of inflammatory bowel disease.","authors":"Fei Jiang, Min Wu, Rongpeng Li","doi":"10.1093/pcmedi/pbad031","DOIUrl":"10.1093/pcmedi/pbad031","url":null,"abstract":"<p><p>Inflammatory bowel diseases (IBD) are a group of chronic relapsing gastrointestinal inflammatory diseases with significant global incidence. Although the pathomechanism of IBD has been extensively investigated, several aspects of its pathogenesis remain unclear. Long non-coding RNAs (lncRNAs) are transcripts with more than 200 nucleotides in length that have potential protein-coding functions. LncRNAs play important roles in biological processes such as epigenetic modification, transcriptional regulation and post-transcriptional regulation. In this review, we summarize recent advances in research on IBD-related lncRNAs from the perspective of the overall intestinal microenvironment, as well as their potential roles as immune regulators, diagnostic biomarkers and therapeutic targets or agents for IBD.</p>","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":5.3,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10757071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chao Ye, Anmin Wang, Wei Li, Wenyuan Li, Qi shen, Zhangfei Wang, Li Xie, Qiuxia Jiang, Kaiguang Zhang, Shu Zhu
{"title":"Prealbumin as a prognostic indicator for hospital readmission of ulcerative colitis patients","authors":"Chao Ye, Anmin Wang, Wei Li, Wenyuan Li, Qi shen, Zhangfei Wang, Li Xie, Qiuxia Jiang, Kaiguang Zhang, Shu Zhu","doi":"10.1093/pcmedi/pbad026","DOIUrl":"https://doi.org/10.1093/pcmedi/pbad026","url":null,"abstract":"","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135186888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：